Openbookopenbook
Equity
PureTech Health plc(PRTC)
GBX --+0.00%
Reward46Moderate
Risk46Moderate
📊75%Data
Strong 793% profit margin · Revenue growing 543% YoY
PRTC
+0.0 · +0.00%
GBX · LSE
PureTech Health plc | Healthcare
Balanced
Market Cap:298.72M
ℹ️
Reward Rating
46
Moderate
Bottom 25% (model universe)
75% data coverage
ℹ️
Risk Rating
46
Moderate
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on PRTC to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 510p.

What is PureTech Health plc?

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.

PRTC · Verdict

Moderate reward · moderate risk

PRTC stands out on balance sheet and profitability, but watch the cash flow signal.

Based on 88% data coverage

PRTC · Verdict

What’s working & what to watch

Strengths 3

  • Balance sheet73/100

    Interest covered 3.4×

  • Profitability65/100

    1240% net margin · 9% ROE

  • Volatility65/100

    Above average

Watchouts 2

  • Cash flow29/100

    -3114% free-cash-flow margin

  • Growth34/100

    Revenue -24.4% CAGR

Model-based scoring. For information only — not financial advice.

What is PureTech Health plc?

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 298.72M, and a P/E ratio of 9.5x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Discount reflects uncertainty around future performance.

OpenBook Logo Analysis

Reward: Moderate (46)

The scoring profile indicates limited reward potential at this time, with profitability and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap298.72M
P/E Ratio9.5077
Dividend YieldN/A
52 Week High148
52 Week Low100.4
Last AnnualDecember
IPO DateN/A
IncorporatedUK
Shares Outstanding242M
No. of Employees56
IndustryBiotechnology
ExchangeLSE
Beta0.688
CurrencyGBX · Reports in USD
Websitewww.puretechhealth.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.